PDCD1 and hepatocellular carcinoma: Thereafter, regorafenib, cabozantinib, ramucirumab, and two programmed cell death protein 1 (PD-1) inhibitors, pembrolizumab and nivolumab which demonstrated objective response rates of 15-20%, were approved in the second- and third-line settings for advanced HCC 4, 7.